Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones

- Announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in r/r AML patients ages 55+; achieved primary endpoint of dCR with high...

Related Keywords

United States ,American ,Sandesh Seth ,Hans Vitzthum ,American Society Of Hematology ,Oncology Group ,Epicentrx Inc ,National Institutes Of Health ,Lifesci Advisors ,Columbia University ,Novartis ,Actinium Pharmaceuticals Inc ,Development Agreement ,Exchange Commission ,Eastern Cooperative Oncology Group ,National Cancer Institute ,Experimental Therapeutics Clinical Trials Network ,Lg Chem Company ,Memorial Sloan Kettering Cancer Center ,Early Access Program ,Prnewswire Actinium Pharmaceuticals Inc ,National Clinical Trials Network ,International Blood Marrow Transplant Research ,Cancer Therapy Evaluation Program ,Astellas Pharma Inc ,Alliance For Clinical Trials In Oncology ,American College Of Radiology Imaging Network ,American Association For Cancer Research ,Columbia University Research Collaboration ,Bone Marrow Transplant ,Cooperative Research ,National Institutes ,Recent Business Highlights ,Data From ,Cellular Therapy Meetings ,American Society ,Cellular Therapy ,International Blood ,Marrow Transplant Research ,Biologics License Application ,From Actimaba Combination Trials ,Annual Meeting ,Complete Remission ,Therapy Evaluation Program ,American College ,Radiology Imaging Network ,Southwest Oncology Group ,Clinical Trials ,American Association ,Cancer Research ,University Research Collaboration ,Commercial Leader ,Caroline Yarbrough ,Chief Commercial ,Marketing Authorization Application ,Year Ended December ,Investment Position ,Pivotal Phase ,About Actinium Pharmaceuticals ,Elderly Relapsed ,Refractory Acute Myeloid Leukemia ,Looking Statements ,Actinium Pharmaceuticals ,Sci Advisors ,Nc ,